Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 7/20 | 0.38 |
| ▸ | BCAT1 | P54687 | 7/20 | 0.38 |
| ▸ | ALPL | P05186 | 6/20 | 0.36 |
| ▸ | ALPI | P09923 | 6/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | USP14 | P54578 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7694103 | 0.81 | MEN1 (0.40) | BCAT2BCAT1ALPLALPITRPV4 | |
| SCHEMBL8193399 | 0.79 | ALPL (0.39) | BCAT2BCAT1ALPLALPIALDH1A1 | |
| SCHEMBL7085889 | 0.72 | TRPV4 (0.37) | BCAT2BCAT1ALPLALPITRPV4 | |
| SCHEMBL7692441 | 0.71 | BCAT2 (0.39) | BCAT2BCAT1TRPV4USP14 | |
| SCHEMBL8193759 | 0.71 | BCAT2 (0.40) | BCAT2BCAT1TRPV4USP14 | |
| SCHEMBL5922790 | 0.69 | BCAT1 (0.67) | BCAT2BCAT1 | |
| SCHEMBL7499656 | 0.69 | BCAT2 (0.41) | BCAT2BCAT1TRPV4USP14 | |
| SCHEMBL9126592 | 0.68 | L3MBTL1 (0.35) | TRPV4CYP11B1CYP11B2 | |
| SCHEMBL8927953 | 0.68 | BCAT2 (0.40) | BCAT2BCAT1TRPV4CYP11B1CYP11B2 | |
| SCHEMBL8190553 | 0.68 | AR (0.42) | BCAT2BCAT1TRPV4ALDH1A1USP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1030846-B1 | METHOD FOR PRODUCING AR(ALK)YLURACILES, NOVEL CORRESPONDING INTERMEDIATE PRODUCTS AND METHOD FOR PRODUCING SAID INTERMEDIATE PRODUCTS | BAYER CROPSCIENCE AG (DE) | 2003-07-16 | — | — | EP | disclosed |
| US-6476224-B2 | N-(4-CYANO-2,5- DIFLUORO-PHENYL) -3-(DIMETHYLAMINOCARBONYLAMINO)-4,4,4-TRIFLUORO-2-BUTENAMIDE AND 1,2-DIMETHOXYETHANE ARE HEATED TO FORM AR(ALK)YL URACIL COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-05 | — | — | US | disclosed |
| US-20020022727-A1 | Method for producing ar(alk)yluraciles, novel corresponding intermediate products and method for producing said intermediate products | GALLENKAMP BERND (DE) | 2002-02-21 | — | — | US | disclosed |
| US-6225470-B1 | HEATING SUBSTITUTED AMINOALKENAMIDES IN PRESENCE OF DILUENTS TO PRODUCE AR(ALK)YLURACIL | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-01 | — | — | US | disclosed |
| EP-1030846-A1 | METHOD FOR PRODUCING AR(ALK)YLURACILES, NOVEL CORRESPONDING INTERMEDIATE PRODUCTS AND METHOD FOR PRODUCING SAID INTERMEDIATE PRODUCTS | BAYER AG (DE) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999025698-A1 | METHOD FOR PRODUCING AR(ALK)YLURACILES, NOVEL CORRESPONDING INTERMEDIATE PRODUCTS AND METHOD FOR PRODUCING SAID INTERMEDIATE PRODUCTS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022727-A1 | Method for producing ar(alk)yluraciles, novel corresponding intermediate products and method for producing said intermediate products | ALK, ALKBH5, ALKBH1 | BCAT2 796/4885BCAT1 895/4885ALPL 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.